Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

A small diversity library of α-methyl amide analogs of sulindac for probing anticancer structure-activity relationships.

Mathew B, Snowden TS, Connelly MC, Guy RK, Reynolds RC.

Bioorg Med Chem Lett. 2018 Jul 1;28(12):2136-2142. doi: 10.1016/j.bmcl.2018.05.023. Epub 2018 May 10.

2.

Oxazole and thiazole analogs of sulindac for cancer prevention.

Mathew B, Hobrath JV, Connelly MC, Guy RK, Reynolds RC.

Future Med Chem. 2018 Apr 1;10(7):743-753. doi: 10.4155/fmc-2017-0182. Epub 2018 Apr 19.

3.

Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation.

Hammill JT, Scott DC, Min J, Connelly MC, Holbrook G, Zhu F, Matheny A, Yang L, Singh B, Schulman BA, Guy RK.

J Med Chem. 2018 Apr 12;61(7):2680-2693. doi: 10.1021/acs.jmedchem.7b01277. Epub 2018 Mar 26.

PMID:
29547696
4.

Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation.

Hammill JT, Bhasin D, Scott DC, Min J, Chen Y, Lu Y, Yang L, Kim HS, Connelly MC, Hammill C, Holbrook G, Jeffries C, Singh B, Schulman BA, Guy RK.

J Med Chem. 2018 Apr 12;61(7):2694-2706. doi: 10.1021/acs.jmedchem.7b01282. Epub 2018 Mar 26.

PMID:
29547693
5.

Amine Containing Analogs of Sulindac for Cancer Prevention.

Mathew B, Hobrath JV, Connelly MC, Guy RK, Reynolds RC.

Open Med Chem J. 2018 Jan 31;12:1-12. doi: 10.2174/1874104501812010001. eCollection 2018.

6.

Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders.

Foulk B, Schaffer M, Gross S, Rao C, Smirnov D, Connelly MC, Chaturvedi S, Reddy M, Brittingham G, Mata M, Repollet M, Rojas C, Auclair D, DeRome M; MMRF CoMMpass Network, Weiss B, Sasser AK.

Br J Haematol. 2018 Jan;180(1):71-81. doi: 10.1111/bjh.15003. Epub 2017 Nov 5.

PMID:
29105742
7.

A Whole Blood Molecular Signature for Acute Myocardial Infarction.

Muse ED, Kramer ER, Wang H, Barrett P, Parviz F, Novotny MA, Lasken RS, Jatkoe TA, Oliveira G, Peng H, Lu J, Connelly MC, Schilling K, Rao C, Torkamani A, Topol EJ.

Sci Rep. 2017 Sep 25;7(1):12268. doi: 10.1038/s41598-017-12166-0.

8.

Diverse amide analogs of sulindac for cancer treatment and prevention.

Mathew B, Hobrath JV, Connelly MC, Kiplin Guy R, Reynolds RC.

Bioorg Med Chem Lett. 2017 Oct 15;27(20):4614-4621. doi: 10.1016/j.bmcl.2017.09.022. Epub 2017 Sep 13.

9.

Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.

Jarusiewicz JA, Jeon JY, Connelly MC, Chen Y, Yang L, Baker SD, Guy RK.

ACS Omega. 2017 May 31;2(5):1985-2009. doi: 10.1021/acsomega.7b00144. Epub 2017 May 10.

10.

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.

Salgia R, Weaver RW, McCleod M, Stille JR, Yan SB, Roberson S, Polzer J, Flynt A, Raddad E, Peek VL, Wijayawardana SR, Um SL, Gross S, Connelly MC, Morano C, Repollet M, Sanders R, Baeten K, D'Haese D, Spigel DR.

Invest New Drugs. 2017 Jun;35(3):334-344. doi: 10.1007/s10637-017-0446-z. Epub 2017 Mar 15.

11.

Screening and Development of New Inhibitors of FtsZ from M. Tuberculosis.

Mathew B, Hobrath JV, Ross L, Connelly MC, Lofton H, Rajagopalan M, Guy RK, Reynolds RC.

PLoS One. 2016 Oct 21;11(10):e0164100. doi: 10.1371/journal.pone.0164100. eCollection 2016.

12.

Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance.

Paoletti C, Larios JM, Muñiz MC, Aung K, Cannell EM, Darga EP, Kidwell KM, Thomas DG, Tokudome N, Brown ME, Connelly MC, Chianese DA, Schott AF, Henry NL, Rae JM, Hayes DF.

Mol Oncol. 2016 Aug;10(7):1078-85. doi: 10.1016/j.molonc.2016.04.006. Epub 2016 Apr 29.

13.

Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.

Min J, Guo K, Suryadevara PK, Zhu F, Holbrook G, Chen Y, Feau C, Young BM, Lemoff A, Connelly MC, Kastan MB, Guy RK.

J Med Chem. 2016 Jan 28;59(2):559-77. doi: 10.1021/acs.jmedchem.5b01092. Epub 2016 Jan 12.

PMID:
26632965
14.

Potent Plasmodium falciparum gametocytocidal activity of diaminonaphthoquinones, lead antimalarial chemotypes identified in an antimalarial compound screen.

Tanaka TQ, Guiguemde WA, Barnett DS, Maron MI, Min J, Connelly MC, Suryadevara PK, Guy RK, Williamson KC.

Antimicrob Agents Chemother. 2015 Mar;59(3):1389-97. doi: 10.1128/AAC.01930-13. Epub 2014 Dec 15.

15.

Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.

Paoletti C, Muñiz MC, Thomas DG, Griffith KA, Kidwell KM, Tokudome N, Brown ME, Aung K, Miller MC, Blossom DL, Schott AF, Henry NL, Rae JM, Connelly MC, Chianese DA, Hayes DF.

Clin Cancer Res. 2015 Jun 1;21(11):2487-98. doi: 10.1158/1078-0432.CCR-14-1913. Epub 2014 Nov 7.

16.

Dihydroquinazolinone inhibitors of proliferation of blood and liver stage malaria parasites.

Derbyshire ER, Min J, Guiguemde WA, Clark JA, Connelly MC, Magalhães AD, Guy RK, Clardy J.

Antimicrob Agents Chemother. 2014;58(3):1516-22. doi: 10.1128/AAC.02148-13. Epub 2013 Dec 23.

17.

Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei.

Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4127-31. doi: 10.1016/j.bmcl.2013.05.049. Epub 2013 May 23.

PMID:
23746473
18.

Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer.

Smerage JB, Budd GT, Doyle GV, Brown M, Paoletti C, Muniz M, Miller MC, Repollet MI, Chianese DA, Connelly MC, Terstappen LW, Hayes DF.

Mol Oncol. 2013 Jun;7(3):680-92. doi: 10.1016/j.molonc.2013.02.013. Epub 2013 Mar 14.

19.

Optimization of chloronitrobenzamides (CNBs) as therapeutic leads for human African trypanosomiasis (HAT).

Hwang JY, Smithson D, Zhu F, Holbrook G, Connelly MC, Kaiser M, Brun R, Guy RK.

J Med Chem. 2013 Apr 11;56(7):2850-60. doi: 10.1021/jm301687p. Epub 2013 Mar 26.

PMID:
23484493
20.

Antiplasmodial activity and cytotoxicity of 10β-aminoquinolinylethylethers of artemisinin.

N'Da DD, Lombard MC, Clark JA, Connelly MC, Matheny AL, Sigal M, Guy KR.

Drug Res (Stuttg). 2013 Feb;63(2):104-8. doi: 10.1055/s-0032-1333295. Epub 2013 Feb 20.

PMID:
23427052
21.

Synthesis and evaluation of methylsulfonylnitrobenzamides (MSNBAs) as inhibitors of the thyroid hormone receptor-coactivator interaction.

Hwang JY, Attia RR, Carrillo AK, Connelly MC, Guy RK.

Bioorg Med Chem Lett. 2013 Mar 15;23(6):1891-5. doi: 10.1016/j.bmcl.2012.12.055. Epub 2013 Jan 8.

22.

Discovery of novel antimalarial compounds enabled by QSAR-based virtual screening.

Zhang L, Fourches D, Sedykh A, Zhu H, Golbraikh A, Ekins S, Clark J, Connelly MC, Sigal M, Hodges D, Guiguemde A, Guy RK, Tropsha A.

J Chem Inf Model. 2013 Feb 25;53(2):475-92. doi: 10.1021/ci300421n. Epub 2013 Jan 23.

23.

Antimalarial activity of 10-alkyl/aryl esters and -aminoethylethers of artemisinin.

Cloete TT, Krebs HJ, Clark JA, Connelly MC, Orcutt A, Sigal MS, Guy RK, N'Da DD.

Bioorg Chem. 2013 Feb;46:10-6. doi: 10.1016/j.bioorg.2012.10.002. Epub 2012 Nov 3.

PMID:
23247255
24.

Lead optimization of antimalarial propafenone analogues.

Lowes D, Pradhan A, Iyer LV, Parman T, Gow J, Zhu F, Furimsky A, Lemoff A, Guiguemde WA, Sigal M, Clark JA, Wilson E, Tang L, Connelly MC, Derisi JL, Kyle DE, Mirsalis J, Guy RK.

J Med Chem. 2012 Jul 12;55(13):6087-93. doi: 10.1021/jm300286a. Epub 2012 Jun 29.

25.

Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.

Zhang Y, Clark JA, Connelly MC, Zhu F, Min J, Guiguemde WA, Pradhan A, Iyer L, Furimsky A, Gow J, Parman T, El Mazouni F, Phillips MA, Kyle DE, Mirsalis J, Guy RK.

J Med Chem. 2012 May 10;55(9):4205-19. doi: 10.1021/jm201642z. Epub 2012 Apr 18.

26.

Synthesis and evaluation of sulfonylnitrophenylthiazoles (SNPTs) as thyroid hormone receptor-coactivator interaction inhibitors.

Hwang JY, Attia RR, Zhu F, Yang L, Lemoff A, Jeffries C, Connelly MC, Guy RK.

J Med Chem. 2012 Mar 8;55(5):2301-10. doi: 10.1021/jm201546m. Epub 2012 Feb 23.

27.

Optimization of propafenone analogues as antimalarial leads.

Lowes DJ, Guiguemde WA, Connelly MC, Zhu F, Sigal MS, Clark JA, Lemoff AS, Derisi JL, Wilson EB, Guy RK.

J Med Chem. 2011 Nov 10;54(21):7477-85. doi: 10.1021/jm2005546. Epub 2011 Oct 10.

28.

Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity.

Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.

J Med Chem. 2011 Oct 27;54(20):7084-93. doi: 10.1021/jm200636z. Epub 2011 Sep 26.

29.

A structure-activity relationship study of small-molecule inhibitors of GLI1-mediated transcription.

Actis M, Connelly MC, Mayasundari A, Punchihewa C, Fujii N.

Biopolymers. 2011 Jan;95(1):24-30. doi: 10.1002/bip.21544.

PMID:
20872873
30.

Amide conjugates of ketoprofen and indole as inhibitors of Gli1-mediated transcription in the Hedgehog pathway.

Mahindroo N, Connelly MC, Punchihewa C, Yang L, Yan B, Fujii N.

Bioorg Med Chem. 2010 Jul 1;18(13):4801-11. doi: 10.1016/j.bmc.2010.05.001. Epub 2010 May 7.

31.

Synthesis and structure-activity relationships of antimalarial 4-oxo-3-carboxyl quinolones.

Zhang Y, Guiguemde WA, Sigal M, Zhu F, Connelly MC, Nwaka S, Guy RK.

Bioorg Med Chem. 2010 Apr 1;18(7):2756-66. doi: 10.1016/j.bmc.2010.02.013. Epub 2010 Feb 11.

32.

Structure-activity relationships and cancer-cell selective toxicity of novel inhibitors of glioma-associated oncogene homologue 1 (Gli1) mediated transcription.

Mahindroo N, Connelly MC, Punchihewa C, Kimura H, Smeltzer MP, Wu S, Fujii N.

J Med Chem. 2009 Jul 23;52(14):4277-87. doi: 10.1021/jm900106f.

33.

Physiological stress induces the metastasis marker AGR2 in breast cancer cells.

Zweitzig DR, Smirnov DA, Connelly MC, Terstappen LW, O'Hara SM, Moran E.

Mol Cell Biochem. 2007 Dec;306(1-2):255-60. Epub 2007 Aug 11.

PMID:
17694278
34.

Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas.

Rowand JL, Martin G, Doyle GV, Miller MC, Pierce MS, Connelly MC, Rao C, Terstappen LW.

Cytometry A. 2007 Feb;71(2):105-13.

35.

Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas.

Smirnov DA, Foulk BW, Doyle GV, Connelly MC, Terstappen LW, O'Hara SM.

Cancer Res. 2006 Mar 15;66(6):2918-22.

36.

Global gene expression profiling of circulating tumor cells.

Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pienta KJ, Meropol NJ, Weiner LM, Cohen SJ, Moreno JG, Connelly MC, Terstappen LW, O'Hara SM.

Cancer Res. 2005 Jun 15;65(12):4993-7.

37.

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.

Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW.

Clin Cancer Res. 2004 Oct 15;10(20):6897-904.

38.

Mouse embryos cloned from brain tumors.

Li L, Connelly MC, Wetmore C, Curran T, Morgan JI.

Cancer Res. 2003 Jun 1;63(11):2733-6.

39.

Cellular factors for resistance against antiretroviral agents.

Fridland A, Connelly MC, Robbins BL.

Antivir Ther. 2000 Sep;5(3):181-5. Review.

PMID:
11075937
40.

MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs.

Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland A.

Nat Med. 1999 Sep;5(9):1048-51.

PMID:
10470083
41.

Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication.

Pisarev VM, Lee SH, Connelly MC, Fridland A.

Mol Pharmacol. 1997 Jul;52(1):63-8.

42.
43.

Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells.

Robbins BL, Greenhaw J, Connelly MC, Fridland A.

Antimicrob Agents Chemother. 1995 Oct;39(10):2304-8.

44.

Standardization of absolute CD4+ lymphocyte counts across laboratories: an evaluation of the Ortho CytoronAbsolute flow cytometry system on normal donors.

Connelly MC, Knight M, Giorgi JV, Kagan J, Landay AL, Parker JW, Page E, Spino C, Wilkening C, Mercolino TJ.

Cytometry. 1995 Sep 15;22(3):200-10.

45.

Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.

Aduma P, Connelly MC, Srinivas RV, Fridland A.

Mol Pharmacol. 1995 Apr;47(4):816-22.

PMID:
7723743
46.

Immunologic differentiation of absolute lymphocyte count with an integrated flow cytometric system: a new concept for absolute T cell subset determinations.

Mercolino TJ, Connelly MC, Meyer EJ, Knight MD, Parker JW, Stelzer GT, DeChirico G.

Cytometry. 1995 Mar 15;22(1):48-59.

48.

Detection of membrane and intracellular antigens by flow cytometry following ORTHO PermeaFix fixation.

Pizzolo G, Vincenzi C, Nadali G, Veneri D, Vinante F, Chilosi M, Basso G, Connelly MC, Janossy G.

Leukemia. 1994 Apr;8(4):672-6.

PMID:
8152264
49.

Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates.

Srinivas RV, Robbins BL, Connelly MC, Gong YF, Bischofberger N, Fridland A.

Antimicrob Agents Chemother. 1993 Oct;37(10):2247-50.

50.

Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells.

Connelly MC, Robbins BL, Fridland A.

Biochem Pharmacol. 1993 Sep 14;46(6):1053-7.

PMID:
8216348

Supplemental Content

Loading ...
Support Center